Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Prontogest (Progesterone) in Healthy Post-Menopausal Women
NCT07495007Phase 1Completed
- Sponsor
- Zi Diligence Biocenter
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of progesterone in postmenopause (2 arms), sponsored by Zi Diligence Biocenter. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 72 hours. Started Nov 2025; status: completed.
02
Drugs
progesterone
03
Conditions
postmenopause
Beyond the preview
Go deeper on NCT07495007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495007.